Introduction {#s1}
============

Hedgehog (HH) signaling plays a critical role in a variety of normal cellular processes. It is pivotal in embryogenesis, regulation of the epithelial-to-mesenchymal transition, the patterning of a diverse range of vertebrate structures in a variety of organs, maintenance of adult tissue homeostasis, tissue repair, cellular proliferation, and in cell survival [@pone.0013054-Lum1], [@pone.0013054-Hooper1], [@pone.0013054-Katoh1], [@pone.0013054-RuiziAltaba1], [@pone.0013054-Yu1], [@pone.0013054-Kasper1], [@pone.0013054-Yoon1], [@pone.0013054-Katoh2], [@pone.0013054-Regl1]. The canonical HH pathway is also critical to normal mammalian gastrointestinal development, where it is involved in the coordinate regulation of differentiation of normal intestinal villi [@pone.0013054-Varnat1], [@pone.0013054-Alinger1], [@pone.0013054-vandenBrink1]. Thus, in the normal gastrointestinal tract, HH ligands are induced in the differentiated cells around the villous surface, generating a negative feedback loop to inhibit canonical WNT signaling in the basal cells of the crypt, thereby protecting differentiated cells from the proliferative effects of WNT [@pone.0013054-Katoh3]. Activation of the canonical HH signaling pathway comprises the binding of HH ligands to the membrane receptor Patched (PTCH1), which becomes internalized leading to the activation of the signaling molecule Smoothened (SMO) via release from PTC-mediated suppression. SMO activates the final arbiter of HH signaling, the GLI family of transcription factors that bind to the GACCACCCA-like consensus binding element in promoter sequences to transcriptionally regulate HH target genes [@pone.0013054-Katoh1], [@pone.0013054-Kasper2], [@pone.0013054-Thiyagarajan1]. GLI1 and GLI2, the transcriptional activators of HH signaling, possess distinct as well as overlapping functions that involve activator (GLI1 and GLI2) or repressor (GLI2) activities [@pone.0013054-Eichberger1]; however, their roles in the regulation of HH-driven cellular proliferation, survival or cell death processes are poorly understood. Historically, GLI1 has been considered the most reliable marker of HH pathway activity, however GLI2 appears to be the primary activator of HH signaling, with GLI1 as a transcriptional target of GLI2 [@pone.0013054-Katoh1], [@pone.0013054-Yoon1], leading to augmentation of HH signaling both quantitatively as well as qualitatively [@pone.0013054-Eichberger1]. An important feature of GLI proteins is that their biological activity is context-dependent, influenced by the cellular environment [@pone.0013054-RuiziAltaba2], [@pone.0013054-Nguyen1].

Activation of the canonical HH signaling cascade is aberrantly activated and well known to play a critical role in oncogenesis and maintenance of the malignant phenotype in several types of human cancers. Such activation involves amplification of GLI1 or GLI2, mutations in PTC or SMO, or dysregulated gene expression [@pone.0013054-Katoh1], [@pone.0013054-RuiziAltaba1]; these malignant cells are also sensitive to the small molecule inhibitor that targets SMO, cyclopamine [@pone.0013054-RuiziAltaba1], [@pone.0013054-Sanchez1], [@pone.0013054-Stecca1], [@pone.0013054-Feldmann1], [@pone.0013054-Sarangi1], [@pone.0013054-Dormoy1]. Colon carcinomas are thought to derive from constitutive activation of WNT signaling by mutation of the APC or β-CATENIN genes, while the involvement of the HH signaling pathway is not as clear. In gastrointestinal malignancies, transcriptional up-regulation of HH ligands has been identified as the predominant activator of HH signaling in these diseases (reviewed in [@pone.0013054-Katoh1]). In addition, there is emerging evidence that HH signaling is involved in colorectal carcinogenesis [@pone.0013054-Yoshikawa1], [@pone.0013054-Bian1], colon carcinoma stem cell self renewal, and in the metastatic behavior of advanced colon cancers [@pone.0013054-Varnat2]. However, genomic approaches to elucidate the role of HH signaling in cancers in general are lacking, regulatory genes downstream of GLI1 and GLI2 that function in cellular proliferation, survival, and maintenance of the malignant HH phenotype remain incompletely characterized [@pone.0013054-Yu1], and data derived on HH signaling in colon cancer is extremely limited.

Cellular proliferation is driven by progression of cells through the cell cycle consisting of sequential passage through G1, S, G2 and M phases. Cyclin-dependent kinases (CDKs) associate with cyclins to drive the cell cycle machinery [@pone.0013054-Nurse1], [@pone.0013054-Berger1]. Thus, CDK2 associates with CYCLIN E at the G1/S transition and with CYCLIN A during S-phase, CDK4 and CDK6 bind to CYCLIN D during progression at G1/S, while CDC2 complexes with CYCLIN A at G2, and with CYCLIN B during the G2/M transition. CDC25 family members also regulate cell cycle progression through dephosphorylation of the CDKs [@pone.0013054-Stark1], [@pone.0013054-McDonald1]. CDK inhibitors, including p21^Cip1^ [@pone.0013054-Stark1], [@pone.0013054-Harper1] and p15^Ink4b^ \[[@pone.0013054-Choi1], bind to cyclin-CDK complexes during the cell cycle transition, in particular at G1/S (p21^Cip1^, p15^Ink4b^;[@pone.0013054-Choi1]) and G2/M (p21^Cip1^;[@pone.0013054-Stark1]), and can also induce cell cycle arrest at the G1/S boundary following cytostatic signals through functional inhibition of cyclin-CDK complexes. The E2F family of transcription factors also regulates the expression of genes required for the G1/S transition, in particular genes involved in the activation of the DNA replication machinery, and DNA repair [@pone.0013054-Polager1].

cDNA microarray technology has provided the ability to study the expression of thousands of genes simultaneously, and is an important tool in the dissection of signal transduction pathways. For the HH signaling cascade, HH/GLI target gene expression has been examined following EGF stimulation [@pone.0013054-Kasper1] or inducible GLI1 [@pone.0013054-Eichberger1] or GLI2 [@pone.0013054-Regl1] gene activation in human keratinocytes, or in GLI1-induced cell transformation [@pone.0013054-Yoon1]. To identify unique downstream targets of the GLI genes that function in cellular proliferation in the context of colon carcinoma, we employed a small molecule inhibitor of both GLI1 and GLI2, GANT61, identified in a cell-based small molecule screen for inhibitors of GLI1-mediated transcription [@pone.0013054-Lauth1]. GANT61 acts in the nucleus to block GLI1 function, inhibits both GLI1- and GLI2- mediated transcription, and demonstrates a high degree of selectivity for HH/GLI signaling [@pone.0013054-Lauth1]. Thus, GANT61 acts downstream of cyclopamine (targeting SMO) to inhibit the final determinants of HH transcriptional regulation.

In two human colon carcinoma cell lines, HT29 and GC3/c1, inhibiting the HH signaling pathway using GANT61 decreased expression of GLI1, GLI2 and the HH ligand receptor, PTCH1, and inhibited proliferation by inducing cellular accumulation at the G1/S boundary 24 hr after treatment, determined by flow cytometric analysis. On further detailed analysis using cDNA microarray gene expression profiling and quantitative Real-Time PCR, p21^Cip1^ (CDKN1A) and p15^Ink4b^ (CDKN2B), that can elicit the G1/S checkpoint, were up-regulated, while genes that further determine entry from G1 to S-phase including E2F2, CYCLIN E2 (CCNE2), CDC25A and CDK2 were decreased in expression. Concomitant with decreased G1 to S-phase progression, decreased expression of CYCLIN A2 (CCNA2), CDC25C, CYCLIN B2 (CCNB2), CDC20 and CDC2 (CDK1), that regulate the passage of cells through G2/M were also demonstrated. Additional novel genes that are involved in stress response, and the response to DNA damage, not previously identified following termination of HH signaling in human cancer cells, include the early response genes DDIT2 (GADD45G), DDIT3 (GADD153), DDIT4 (REDD1), PPP1R15A (GADD34) and ATF3 that were significantly up-regulated. Genes involved in DNA synthesis and repair (TYMS, TOP2A, TK1, POLE, POLE2), and additional novel genes involved in S-phase progression or DNA damage responses that were significantly down-regulated, include KIAA0101 (p15 \[PAF\]), Replication Factor C variants 2, 3, 4, 5, CDT1, the E2F transcription factors CDCA4 and TFDP1, MDC1, FANCD2, PCNA, and the genes involved in DNA repair, RAD51C (XRCC3), RAD54B, RAD51 and HELLS. This study has therefore identified genes that are regulated during the termination of HH-dependent cellular proliferation and survival in colon cancer cells, and involves genes associated with G1/S-phase arrest, DNA damage and stress responses.

Results {#s2}
=======

GANT61 induces down-regulated expression of GLI genes and accumulation of human colon carcinoma cells at G1/S {#s2a}
-------------------------------------------------------------------------------------------------------------

In HT29 and GC3/c1 cells treated with GANT61 (20 µM) for up to 48 hr, expression of the target genes GLI1 and GLI2 were both down-regulated, and also the HH ligand receptor PTCH1, as determined by qRT-PCR ([Figure 1A](#pone-0013054-g001){ref-type="fig"}). Subsequently, HT29 or GC3/c1 cells were treated, in duplicate, with GANT61 (20 µM) followed by PI staining and flow cytometric analysis for the determination of cell cycle distribution between G1, S and G2/M phases ([Figure 1B](#pone-0013054-g001){ref-type="fig"}). In both cell lines, cells accumulated in G1, 24 hr after treatment with GANT61. In GANT61-treated HT29 cells, a 20% increase in G1-phase cells was associated with a corresponding decrease in cells within the G2/M phase (14%) and in S-phase (5%), consistent with a G1/S checkpoint arrest. In GC3/c1 cells, an 8% increase in G1-phase cells at 24 hr after GANT61 treatment also corresponded with a similar reduction in cells in the G2/M phase of the cell cycle ([Figure 1B](#pone-0013054-g001){ref-type="fig"}).

![Expression of GLI1, GLI2, PTCH1 and cell cycle distribution of HT29 and GC3/c1 cells.\
Cells were treated for up to 48 hr with GANT61 (20 µM) or with 0.2% DMSO (vehicle control). (A) qRT-PCR of GLI1, GLI2 and PTCH1 genes from time 0 to 48 hr. (B) DNA was extracted at 24 hr after treatment, stained with propidium iodide, and subsequently analyzed for the effects of inhibition of HH signaling on phase distribution of cells within the cell cycle by flow cytometry.](pone.0013054.g001){#pone-0013054-g001}

cDNA microarray analyses identify changes in gene expression both common and unique to HT29 and GC3/c1 following GANT61 treatment {#s2b}
---------------------------------------------------------------------------------------------------------------------------------

To delineate the changes in gene expression in HT29 and GC3/c1 human colon carcinoma cell lines in response to treatment with the GLI1/GLI2 antagonist, GANT61, the expression of 18,401 human genes was profiled in control cells treated with vehicle (0.2% DMSO) and in cells treated with GANT61 (20 µM) for 24 hr. Genes with a False Discovery Rate (FDR)-adjusted p-value of \<0.001 and fold change \>1.5 were considered Differentially Expressed Genes (DEGs) induced by GANT61 relative to the vehicle control, of which 1,368 genes were differentially expressed in HT29, and 1,002 genes in GC3/c1 cells ([Figure 2](#pone-0013054-g002){ref-type="fig"}). 755 genes or 558 genes were up-regulated, and 613 or 444 genes were down-regulated, in HT29 and GC3/c1 cells, respectively. 763 and 397 genes were differentially expressed and unique to HT29 or GC3/c1, respectively. Of the 763 DEGs unique to HT29, 459 (60%) were up-regulated and 304 (40%) were down-regulated. Similarly, of the 397 DEGs unique to GC3/c1, 262 (66%) were up-regulated and 135 (34%), down-regulated. In contrast, 605 genes representing 3.4% of all genes were differentially expressed that were common to both cell lines; of these, 296 were up-regulated (49%), and 309 (51%) were down-regulated ([Figure 2](#pone-0013054-g002){ref-type="fig"}). All genes common to both HT29 and GC3/c1 that were significantly up-regulated or down-regulated (p\<0.001) are listed in [Tables 1](#pone-0013054-t001){ref-type="table"} and [2](#pone-0013054-t002){ref-type="table"}, respectively.

![Venn diagram summarizing Differentially Expressed Genes (DEGs) in GANT61-treated HT29 and GC3/c1 cells.\
Cells were treated with GANT61 (20 µM) or vehicle alone (0.2% DMSO) for 24 hr, and total RNA extracted as described in [Materials and Methods](#s4){ref-type="sec"}. Changes in gene expression were determined by cDNA microarray gene profiling using the Illumina Human-ref8 V3.0 Bead-Chip array. Genes with a False Discovery Rate (FDR)-adjusted p-value (p\<0.001) and fold change \>1.5 were considered DEGs. Upper panel: up-regulated genes. Lower panel: down-regulated genes. Differential expression for the total, unique up-regulated, unique down-regulated, common up-regulated, and common down-regulated DEGs, are shown.](pone.0013054.g002){#pone-0013054-g002}

10.1371/journal.pone.0013054.t001

###### Up-regulated genes (p\<0.001) common in GANT61-treated HT29 and GC3/c1 cells.

![](pone.0013054.t001){#pone-0013054-t001-1}

  ACCESSION NUMBER    GENE SYMBOL                            DEFINITION                            Fold Change   ACCESSION NUMBER    GENE SYMBOL     DEFINITION                            Fold Change                                  
  ------------------ ------------- -------------------------------------------------------------- ------------- ------------------ ---------------- ------------ --------------------------------------------------------------- ------ -------
  NM_080489.3           SDCBP2                        syndecan binding protein                        12.42           10.83         NM_001008213.1      OPTN                               optineurin                             2.63   2.37
  NM_001042483.1         NUPR1                           nuclear protein 1                            7.96             3.53          NM_000431.1        MVK                             mevalonate kinase                         2.61   2.77
  NM_021187.2           CYP4F11                           cytochrome P450                             7.73             4.27          NM_001550.2       IFRD1              interferon-related developmental regulator 1            2.60   1.84
  NM_001001870.1       C17orf91                 chromosome 17 open reading frame 91                   6.79             3.82          NM_025130.2       HKDC1                     hexokinase domain containing 1                   2.58   4.46
  NM_004864.1            GDF15                    growth differentiation factor 15                    6.61             3.43          NM_002461.1        MVD                   mevalonate (diphospho) decarboxylase                2.57   5.36
  NM_004083.4            DDIT3                   DNA-damage-inducible transcript 3                    6.36             2.35          NM_021626.1       SCPEP1                       serine carboxypeptidase 1                     2.55   1.79
  NM_005130.3           FGFBP1               fibroblast growth factor binding protein 1               5.86            41.19          NM_012424.2      RPS6KC1                      ribosomal protein S6 kinase                    2.53   2.03
  NM_022060.2            ABHD4                    abhydrolase domain containing 4                     5.65             3.07          NM_052839.2       PANX2                               pannexin 2                             2.53   5.61
  NM_015526.1            CLIP3               CAP-GLY domain containing linker protein 3               5.25             2.74          NM_021173.2       POLD4                        polymerase (DNA-directed)                     2.51   1.71
  NM_000389.2           CDKN1A                  cyclin-dependent kinase inhibitor 1A                  5.21             2.02          NM_020400.4       LPAR5                    lysophosphatidic acid receptor 5                  2.50   2.17
  NM_002298.2            LCP1                      lymphocyte cytosolic protein 1                     5.02             8.60          NM_007075.3       WDR45                           WD repeat domain 45                        2.50   1.61
  NM_019058.2            DDIT4                   DNA-damage-inducible transcript 4                    4.91             3.91          NM_001909.3        CTSD                               cathepsin D                            2.50   1.68
  NM_031412.2          GABARAPL1             GABA(A) receptor-associated protein like 1               4.73             4.81          NM_022157.2       RRAGC                        Ras-related GTP binding C                     2.48   2.80
  NM_033285.2          TP53INP1            tumor protein p53 inducible nuclear protein 1              4.71             2.80          NM_138573.2        NRG4                              neuregulin 4                            2.48   2.69
  NM_001001342.1        BLOC1S2         biogenesis of lysosome-related organelles complex-1           4.68             3.95          NM_201545.1       LGALS8                                lectin                               2.46   2.81
  NM_153282.1            HYAL1                       hyaluronoglucosaminidase 1                       4.57            22.29          NM_175738.3       RAB37                    RAB37, member RAS oncogene family                 2.40   3.53
  NM_012385.1             P8                                 p8 protein                               4.57             4.01          NM_012257.3        HBP1                     HMG-box transcription factor 1                   2.40   1.65
  NM_016061.1            YPEL5                             yippee-like 5                              4.39             3.98         NM_001083617.1     RB1CC1                      RB1-inducible coiled-coil 1                    2.39   1.68
  NM_145693.1            LPIN1                                lipin 1                                 4.39             3.59          NM_153341.1       RNF19B                        ring finger protein 19B                      2.38   1.61
  NM_019600.1          KIAA1370                               KIAA1370                                4.13             2.73          NM_003129.3        SQLE                           squalene epoxidase                         2.38   3.03
  NM_021009.3             UBC                               ubiquitin C                               4.08             7.52          NM_018045.5       BSDC1                         BSD domain containing 1                      2.38   2.34
  NM_002084.3            GPX3                         glutathione peroxidase 3                        4.05             2.99          NM_003376.4       VEGFA                  vascular endothelial growth factor A                2.37   2.09
  NM_003256.2            TIMP4                   TIMP metallopeptidase inhibitor 4                    4.04             2.02          NM_007028.3       TRIM31                    tripartite motif-containing 31                   2.37   6.54
  NM_198336.1           INSIG1                         insulin induced gene 1                         4.02             9.90          NM_000527.2        LDLR                    low density lipoprotein receptor                  2.35   3.83
  NM_002517.2            NPAS1                     neuronal PAS domain protein 1                      3.95             2.76          NM_024717.3       MCTP1                  multiple C2 domains, transmembrane 1                2.33   2.28
  NM_001040619.1         ATF3                    activating transcription factor 3                    3.90             1.86          NM_198833.1      SERPINB8                     serpin peptidase inhibitor                     2.32   2.07
  NM_006096.2            NDRG1                   N-myc downstream regulated gene 1                    3.89             2.63          NM_023039.2       ANKRA2                ankyrin repeat, family A (RFXANK-like)               2.31   1.82
  NM_003670.1           BHLHB2                basic helix-loop-helix domain containing                3.82             3.68          NM_025047.1       ARL14                     ADP-ribosylation factor-like 14                  2.30   6.15
  NM_002130.6           HMGCS1            3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1            3.75             6.54         NM_001080391.1     SP100                          SP100 nuclear antigen                       2.29   1.90
  NR_003086.1          HSD17B7P2       hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2          3.74             2.83          NM_002395.3        ME1                              malic enzyme 1                           2.29   2.31
  NM_001013680.1       LOC401233                similar to HIV TAT specific factor 1                  3.74             2.10          NM_001360.2       DHCR7                     7-dehydrocholesterol reductase                   2.29   2.73
  NM_006918.4            SC5DL                          sterol-C5-desaturase                          3.68             3.41          NM_032421.2       CLIP2               CAP-GLY domain containing linker protein 2             2.27   1.79
  NM_182980.2           OSGIN1              oxidative stress induced growth inhibitor 1               3.55             4.48          NM_014039.2      C11orf54                 chromosome 11 open reading frame 54                2.27   1.62
  NM_025182.2          KIAA1539                               KIAA1539                                3.49             2.62          NM_017585.2       SLC2A6                        solute carrier family 2                      2.27   2.35
  NM_018677.2            ACSS2            acyl-CoA synthetase short-chain family member 2             3.46             4.68          NM_014330.2      PPP1R15A                        protein phosphatase 1                       2.26   1.63
  NM_001034850.1        FAM134B                 family with sequence similarity 134                   3.44             1.90          NM_145306.2      C10orf35                 chromosome 10 open reading frame 35                2.26   2.19
  NM_153742.3             CTH                cystathionase (cystathionine gamma-lyase)                3.38             2.13          NM_003831.3       RIOK3                              RIO kinase 3                            2.25   1.93
  NM_021158.3            TRIB3                           tribbles homolog 3                           3.34             3.71          NM_006997.2       TACC2          transforming, acidic coiled-coil containing protein 2       2.25   1.95
  NM_000434.2            NEU1                               sialidase 1                               3.28             2.00         NM_001006932.1    RPS6KA2                      ribosomal protein S6 kinase                    2.24   1.68
  NM_001005404.3         YPEL2                             yippee-like 2                              3.22             2.40          NM_000574.2        CD55                              CD55 molecule                           2.23   1.84
  NM_004508.2            IDI1                isopentenyl-diphosphate delta isomerase 1                3.21             4.78          NM_018310.2        BRF2      subunit of RNA polymerase III transcription initiation factor   2.23   2.14
  NM_003151.2            STAT4           signal transducer and activator of transcription 4           3.18             3.85          NM_001491.2       GCNT2                  glucosaminyl (N-acetyl) transferase 2               2.22   4.08
  NM_005165.2            ALDOC                               aldolase C                               3.16             2.44          NM_003567.2       BCAR3                breast cancer anti-estrogen resistance 3              2.21   1.79
  NM_014331.3           SLC7A11                       solute carrier family 7                         3.16             2.54          NM_005488.1        TOM1                             target of myb1                           2.20   1.89
  NM_000104.2           CYP1B1                            cytochrome P450                             3.15             2.41          NM_004462.3       FDFT1               farnesyl-diphosphate farnesyltransferase 1             2.19   2.73
  NM_002340.3             LSS                           lanosterol synthase                           3.14             3.15          NM_019116.2       UBFD1                  ubiquitin family domain containing 1                2.19   1.90
  NM_078487.2           CDKN2B                  cyclin-dependent kinase inhibitor 2B                  3.13             2.13          NM_007105.1     SLC22A18AS                     solute carrier family 22                      2.18   1.81
  NM_002201.4            ISG20              interferon stimulated exonuclease gene 20kDa              3.12             1.91          NM_182491.1      ZFAND2A                              zinc finger                            2.17   2.17
  NM_016315.2            GULP1            GULP, engulfment adaptor PTB domain containing 1            3.11             4.39          NM_181785.2      SLC46A3                       solute carrier family 46                      2.17   2.00
  NM_017983.4            WIPI1                            WD repeat domain                            3.09             2.40          NM_024866.4        ADM2                            adrenomedullin 2                          2.16   1.77
  NM_024165.1            PHF1                           PHD finger protein 1                          3.07             2.42          NM_021133.2       RNASEL                            ribonuclease L                           2.15   2.28
  NM_001995.2            ACSL1             acyl-CoA synthetase long-chain family member 1             3.06             2.86          NM_032548.2       ABTB1            ankyrin repeat and BTB (POZ) domain containing 1          2.14   1.58
  NM_004354.1            CCNG2                               cyclin G2                                3.05             2.64          NM_002153.1      HSD17B2               hydroxysteroid (17-beta) dehydrogenase 2              2.14   2.98
  NM_020739.2            CCPG1                        cell cycle progression 1                        3.04             1.88          NM_006033.2        LIPG                                 lipase                               2.13   2.86
  NM_001017369.1        SC4MOL                     sterol-C4-methyl oxidase-like                      3.03             4.04          NM_020919.2        ALS2                     amyotrophic lateral sclerosis 2                  2.11   1.77
  NM_001031744.1       LOC158160                   hypothetical protein LOC158160                     3.02             2.35          NM_014701.2      KIAA0256                        KIAA0256 gene product                       2.11   2.30
  NM_032409.2            PINK1                     PTEN induced putative kinase 1                     2.98             2.44          NM_001222.2       CAMK2G              calcium/calmodulin-dependent protein kinase            2.11   2.12
  NM_003811.2           TNFSF9               tumor necrosis factor (ligand) superfamily               2.98             3.04          NM_015271.2       TRIM2                      tripartite motif-containing 2                   2.11   1.79
  NM_002357.2            MXD1                        MAX dimerization protein 1                       2.93             2.30          NM_174936.2       PCSK9              proprotein convertase subtilisin/kexin type 9           2.11   4.18
  NM_000777.2           CYP3A5                            cytochrome P450                             2.92             1.77          NM_015713.3       RRM2B                      ribonucleotide reductase M2 B                   2.10   1.66
  NM_001098500.1       KIAA1217                               KIAA1217                                2.88             3.16          NM_005749.2        TOB1                           transducer of ERBB2                        2.09   1.58
  NM_022119.3           PRSS22                                protease                                2.84             3.27          NM_004419.3       DUSP5                     dual specificity phosphatase 5                   2.08   3.61
  NM_004669.2            CLIC3             Homo sapiens chloride intracellular channel 3              2.80             6.19          NM_033028.2        BBS4                         Bardet-Biedl syndrome 4                      2.08   2.04
  NM_080491.1            GAB2                    GRB2-associated binding protein 2                    2.79             2.06          NM_001286.2       CLCN6                           chloride channel 6                         2.07   2.18
  NM_178270.1            ATG4A                   ATG4 autophagy related 4 homolog A                   2.79             1.92         XM_001132495.1    SLC26A11                 PREDICTED:solute carrier family 26                 2.07   1.87
  NM_002770.2            PRSS2                    protease, serine, 2 (trypsin 2)                     2.79             1.64          NM_172070.2       ZNF650                        zinc finger protein 650                      2.07   1.90
  NM_182608.2           ANKRD33                       ankyrin repeat domain 33                        2.74             1.91          NM_004567.2       PFKFB4                  6-phosphofructo-2-kinase/fructose-2                2.07   1.93
  NM_006705.2           GADD45G                growth arrest and DNA-damage-inducible                 2.74             3.01          NM_002555.3      SLC22A18                      solute carrier family 22                      2.06   1.62
  NM_012326.2           MAPRE3                     microtubule-associated protein                     2.73             2.16         NM_001010990.1    HERPUD1        homocysteine-inducible, ubiquitin-like domain member 1       2.06   1.63
  NM_001013251.1        SLC3A2                        solute carrier family 3                         2.72             2.40          NM_198867.1       ALKBH6                   alkB, alkylation repair homolog 6                 2.06   1.65
  NM_016243.2           CYB5R1                       cytochrome b5 reductase 1                        2.72             2.52          NM_000271.3        NPC1                          Niemann-Pick disease                        2.05   2.18
  NM_198129.1            LAMA3                                laminin                                 2.65             3.36          NM_006454.2        MXD4                       MAX dimerization protein 4                     2.05   1.80
  NM_000228.2            LAMB3                                laminin                                 2.65             2.27          NM_021194.2      SLC30A1                       solute carrier family 30                      2.03   1.73
  NM_006608.1            PHTF1              putative homeodomain transcription factor 1               2.64             2.38          NM_173843.1       IL1RN                    interleukin 1 receptor antagonist                 2.03   10.01
  NM_021229.3            NTN4                                 netrin 4                                2.03             2.47          NM_152271.3       LONRF1           LON peptidase N-terminal domain and ring finger 1         1.72   3.04
  NM_002064.1            GLRX                               glutaredoxin                              2.03             1.75          NM_003314.1        TTC1                    tetratricopeptide repeat domain 1                 1.72   1.55
  NM_005896.2            IDH1                        isocitrate dehydrogenase 1                       2.02             2.37          NM_005920.2       MEF2D                       myocyte enhancer factor 2D                     1.71   1.85
  NM_144498.1           OSBPL2                    oxysterol binding protein-like 2                    2.01             1.81          NM_016410.2       CHMP5                      chromatin modifying protein 5                   1.71   2.14
  NM_005115.3             MVP                           major vault protein                           1.99             1.82          NM_001748.3       CAPN2                                calpain 2                             1.70   2.16
  NM_023938.4          C1orf116                 chromosome 1 open reading frame 116                   1.98             3.06          NM_004344.1       CETN2                                 centrin                              1.70   1.54
  NM_024311.2           MFSD11           major facilitator superfamily domain containing 11           1.98             1.80          NM_177947.2       ARMCX3                armadillo repeat containing, X-linked 3              1.70   1.76
  NM_004433.3            ELF3                            E74-like factor 3                            1.97             3.72          NM_000158.2        GBE1                                 glucan                               1.69   1.73
  NM_031229.2            RBCK1           RanBP-type and C3HC4-type zinc finger containing 1           1.97             4.21          NM_052873.1     C14orf179                chromosome 14 open reading frame 179                1.69   1.52
  NM_005564.3            LCN2                               lipocalin 2                               1.97             4.19          NM_020310.2        MNT                            MAX binding protein                        1.69   1.51
  NM_002956.2            CLIP1               CAP-GLY domain containing linker protein 1               1.96             1.62          NM_015367.2      BCL2L13                             BCL2-like 13                            1.69   1.88
  NM_005562.1            LAMC2                            laminin, gamma 2                            1.96             2.01         NM_001005474.1     NFKBIZ        nuclear factor of kappa light polypeptide gene enhancer      1.69   1.72
  NM_000332.2            ATXN1                                ataxin 1                                1.96             1.86          NM_021202.1      TP53INP2            tumor protein p53 inducible nuclear protein 2           1.69   1.89
  NM_001206.2            KLF9                          Kruppel-like factor 9                          1.96             2.19          NM_138448.2       ACYP2                            acylphosphatase 2                         1.68   2.03
  NM_173359.3           EIF4E3      eukaryotic translation initiation factor 4E family member 3       1.95             2.01          NM_003729.1       RTCD1                 RNA terminal phosphate cyclase domain 1              1.67   1.61
  NM_003565.1            ULK1                           unc-51-like kinase 1                          1.95             1.57          NM_030912.2       TRIM8                      tripartite motif-containing 8                   1.67   1.70
  NM_012161.2            FBXL5                F-box and leucine-rich repeat protein 5                 1.95             2.27          NM_018202.3       TMEM57                       transmembrane protein 57                      1.67   1.88
  NM_001079864.1        TAX1BP1     Tax1 (human T-cell leukemia virus type I) binding protein 1       1.93             1.66          NM_018297.2       NGLY1                              N-glycanase 1                           1.66   1.68
  NM_005063.4             SCD                         stearoyl-CoA desaturase                         1.93             4.44          NM_183399.1       RNF14                         ring finger protein 14                       1.66   1.87
  NM_145279.4           MOBKL2C            MOB1, Mps One Binder kinase activator-like 2C              1.92             2.58          NM_032357.2      CCDC115                   coiled-coil domain containing 115                 1.66   1.63
  NM_004055.4            CAPN5                               calpain 5                                1.91             2.05          NM_172037.2       RDH10                        retinol dehydrogenase 10                      1.66   2.20
  NM_175932.1           PSMD13              proteasome (prosome, macropain) 26S subunit               1.91             2.14          NM_012287.3       CENTB2                               centaurin                             1.65   1.62
  NM_002885.1           RAP1GAP                    RAP1 GTPase activating protein                     1.91             2.02          NM_018178.3      GOLPH3L                      golgi phosphoprotein 3-like                    1.65   1.64
  NM_145245.2            EVI5L                ecotropic viral integration site 5-like                 1.90             1.69          NM_025147.3       COQ10B                        coenzyme Q10 homolog B                       1.64   1.54
  NM_021242.3           MID1IP1                      MID1 interacting protein 1                       1.89             1.78          NM_006285.2       TESK1                        testis-specific kinase 1                      1.64   1.61
  NM_006503.2            PSMC4              proteasome (prosome, macropain) 26S subunit               1.89             2.16         NM_001018102.1    GRINL1A                          glutamate receptor                         1.64   1.92
  NM_005975.2            PTK6                        protein tyrosine kinase 6                        1.88             1.97          NM_005476.3        GNE                  glucosamine (UDP-N-acetyl)-2-epimerase               1.64   2.98
  NM_207304.1            MBNL2                           muscleblind-like 2                           1.88             1.63          NR_002204.1       FTHL11          ferritin, heavy polypeptide-like 11 on chromosome 8        1.63   1.79
  NM_000859.1            HMGCR            3-hydroxy-3-methylglutaryl-Coenzyme A reductase             1.88             2.46          NM_053067.1       UBQLN1                              ubiquilin 1                            1.63   1.56
  NM_021021.2            SNTB1                               syntrophin                               1.88             1.64          NM_005895.3       GOLGA3                           golgi autoantigen                         1.63   1.58
  NM_032667.4            BSCL2             Bernardinelli-Seip congenital lipodystrophy 2              1.87             1.73          NM_037370.1      CCNDBP1                    cyclin D-type binding-protein 1                  1.63   1.50
  NM_006022.2           TSC22D1                         TSC22 domain family                           1.87             2.40         NM_001042430.1    FAM164C                  family with sequence similarity 164                1.62   2.01
  NM_012478.3            WBP2                       WW domain binding protein 2                       1.87             1.67          NM_004751.1       GCNT3                  glucosaminyl (N-acetyl) transferase 3               1.62   3.99
  NM_031476.2          CRISPLD2       cysteine-rich secretory protein LCCL domain containing 2        1.87             2.57          NM_004428.2       EFNA1                                ephrin-A1                             1.61   2.10
  NM_017921.1           NPLOC4                 nuclear protein localization 4 homolog                 1.87             1.74          NM_007193.3       ANXA10                              annexin A10                            1.61   2.36
  NM_015508.3           TIPARP               TCDD-inducible poly(ADP-ribose) polymerase               1.86             1.75          NM_018180.2       DHX32                DEAH (Asp-Glu-Ala-His) box polypeptide 32             1.61   1.52
  NM_001376.2           DYNC1H1                 dynein, cytoplasmic 1, heavy chain 1                  1.86             1.50          NM_020202.2        NIT2                            nitrilase family                          1.61   1.62
  NM_144693.1           ZNF558                        zinc finger protein 558                         1.86             1.98          NM_032169.4       ACAD11                 acyl-Coenzyme A dehydrogenase family                1.61   1.73
  NM_003344.2            UBE2H                    ubiquitin-conjugating enzyme E2H                    1.85             2.04          NM_147223.2       NCOA1                     nuclear receptor coactivator 1                   1.60   1.57
  NM_152528.1           WDSUB1      WD repeat, sterile alpha motif and U-box domain containing 1      1.85             1.74          NM_002203.3       ITGA2                                integrin                              1.59   2.49
  NM_001225.3            CASP4            caspase 4, apoptosis-related cysteine peptidase             1.85             1.97          NM_018317.1      TBC1D19                          TBC1 domain family                         1.59   2.18
  NM_001512.2            GSTA4                      glutathione S-transferase A4                      1.84             2.45          NM_002061.2        GCLM                        glutamate-cysteine ligase                     1.59   2.06
  NM_020299.3           AKR1B10                     aldo-keto reductase family 1                      1.83             2.42          NM_019007.3       ARMCX6                armadillo repeat containing, X-linked 6              1.58   1.81
  NM_016143.3           NSFL1C                       NSFL1 (p97) cofactor (p47)                       1.83             2.61          NM_015974.2       CRYL1                          crystallin, lambda 1                        1.58   1.51
  NM_080655.1           C9orf30                  chromosome 9 open reading frame 30                   1.83             1.77          NM_006149.2       LGALS4                                lectin                               1.58   3.12
  NM_001018109.1          PIR                                  pirin                                  1.83             2.67          NM_012233.1      RAB3GAP1              RAB3 GTPase activating protein subunit 1              1.57   1.78
  NR_002200.1            FTHL2           ferritin, heavy polypeptide-like 2 on chromosome 1           1.83             1.62          NM_002808.3       PSMD2               proteasome (prosome, macropain) 26S subunit            1.57   1.72
  NM_005485.3            PARP3                  poly (ADP-ribose) polymerase family                   1.82             1.77         NM_001030001.1     RPS29                          ribosomal protein S29                       1.57   1.61
  NM_058172.3           ANTXR2                        anthrax toxin receptor 2                        1.82             1.88          NM_052849.2       CCDC32                   coiled-coil domain containing 32                  1.57   1.55
  NR_002166.1            SEDLP             spondyloepiphyseal dysplasia, late, pseudogene             1.81             1.88          NM_015484.4        SYF2                              SYF2 homolog                            1.57   1.64
  NM_022449.1            RAB17                       member RAS oncogene family                       1.80             1.64         NM_001093771.1     TXNRD1                        thioredoxin reductase 1                      1.57   1.54
  NM_198310.2            TTC8                    tetratricopeptide repeat domain 8                    1.80             1.83          NM_017707.2       ASAP3         ArfGAP with SH3 domain, ankyrin repeat and PH domain 3       1.57   1.59
  NM_002786.2            PSMA1                proteasome (prosome, macropain) subunit                 1.79             2.54          NM_020412.3       CHMP1B                    chromatin modifying protein 1B                   1.56   1.83
  NM_002796.2            PSMB4                proteasome (prosome, macropain) subunit                 1.78             1.53          NM_017549.3       EPDR1                       ependymin related protein 1                    1.56   1.52
  NR_002201.1           FTHL3P                                ferritin                                1.78             2.10         NM_001080493.2     ZNF823                        zinc finger protein 823                      1.56   1.56
  NM_020225.1            STOX2                            storkhead box 2                             1.78             5.98         NM_001008738.2     FNIP1                    folliculin interacting protein 1                  1.56   1.50
  NM_080725.1            SRXN1                         sulfiredoxin 1 homolog                         1.78             1.67          NM_006343.2       MERTK                  c-mer proto-oncogene tyrosine kinase                1.56   2.12
  NM_015946.4            PELO                              pelota homolog                             1.77             1.58          NM_014851.2       KLHL21                             kelch-like 21                           1.56   2.02
  NM_020751.1            COG6                 component of oligomeric golgi complex 6                 1.77             1.60          NM_002803.2       PSMC2                               proteasome                             1.55   1.77
  NM_001080538.1       LOC441282              similar to aldo-keto reductase family 1                 1.77             2.31          NM_145918.2       CTSL1                              cathepsin L1                            1.55   1.96
  NM_004487.3           GOLGB1                               golgin B1                                1.76             1.82          NM_003846.1       PEX11B                 peroxisomal biogenesis factor 11 beta               1.55   1.92
  NM_145040.2           PRKCDBP                           protein kinase C                            1.76             3.27          NM_014905.2        GLS                                glutaminase                            1.55   2.21
  NM_201557.2            FHL2                      four and a half LIM domains 2                      1.76             1.74          NM_016154.3       RAB4B                       member RAS oncogene family                     1.55   2.22
  NM_015037.2          KIAA0913                               KIAA0913                                1.75             1.52          NM_052901.2      SLC25A25                      solute carrier family 25                      1.54   1.55
  NM_003003.2           SEC14L1                             SEC14-like 1                              1.74             1.94          NM_033212.2      CCDC102A                 coiled-coil domain containing 102A                 1.54   1.75
  NM_001031835.1         PHKB                           phosphorylase kinase                          1.74             1.63          NM_002799.2       PSMB7                 proteasome (prosome, macropain) subunit              1.54   1.56
  NM_016470.6          C20orf111                chromosome 20 open reading frame 111                  1.74             1.54         NM_001031716.1     OBFC2A      oligonucleotide/oligosaccharide-binding fold containing 2A     1.53   1.60
  NM_001080791.1       C15orf57                 chromosome 15 open reading frame 57                   1.74             1.63          NM_015187.3      KIAA0746                          KIAA0746 protein                          1.53   1.62
  NM_002541.2            OGDH             oxoglutarate (alpha-ketoglutarate) dehydrogenase            1.74             1.55          NM_004034.1       ANXA7                               annexin A7                             1.52   1.75
  NM_015922.1            NSDHL              NAD(P) dependent steroid dehydrogenase-like               1.74             2.30          NM_002815.2       PSMD11              proteasome (prosome, macropain) 26S subunit            1.52   1.71
  XM_001128220.1        PLEKHM1       pleckstrin homology domain containing, family M member 1        1.73             1.73          NM_014889.2       PITRM1                     pitrilysin metallopeptidase 1                   1.52   2.15
  NM_004417.2            DUSP1                     dual specificity phosphatase 1                     1.73             1.78          NM_007126.2        VCP                        valosin-containing protein                     1.51   1.79
  NM_003971.3            SPAG9                       sperm associated antigen 9                       1.73             1.80          NM_032017.1       STK40                       serine/threonine kinase 40                     1.50   1.66
  NM_016026.2            RDH11                        retinol dehydrogenase 11                        1.72             1.67          NM_032776.1       JMJD1C                     jumonji domain containing 1C                    1.50   1.81
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###### Down-regulated genes (p\<0.001) common in GANT61-treated HT29 and GC3/c1 cells.
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  ACCESSION NUMBER    GENE SYMBOL                           DEFINITION                            Fold Change   ACCESSION NUMBER    GENE SYMBOL     DEFINITION                             Fold Change                                     
  ------------------ ------------- ------------------------------------------------------------- ------------- ------------------ ---------------- ------------ ------------------------------------------------------------------ ------- -------
  NM_015086.1             DDN                                 dendrin                                −6.81           −2.37          NM_014791.2        MELK                  maternal embryonic leucine zipper kinase               −2.50   −2.09
  NM_001013653.2        LRRC26                   leucine rich repeat containing 26                   −4.77           −2.23          NM_016343.3       CENPF                      centromere protein F, 350/400ka                    −2.50   −2.71
  NM_004091.2            E2F2                       E2F transcription factor 2                       −4.23           −2.26          NM_001789.2       CDC25A                     cell division cycle 25 homolog A                   −2.50   −2.45
  NM_182687.1           PKMYT1       protein kinase, membrane associated tyrosine/threonine 1        −4.17           −4.81          NM_024037.1      C1orf135                  chromosome 1 open reading frame 135                  −2.49   −2.12
  NM_001013653.1       LOC389816                  cytokeratin associated protein                     −3.85           −2.32          NM_017669.2       ERCC6L       excision repair cross-complementing rodent repair deficiency     −2.48   −3.22
  NM_020675.3            SPC25             NDC80 kinetochore complex component, homolog              −3.51           −7.19          NM_031965.2        GSG2                      germ cell associated 2 (haspin)                    -2.47   −2.79
  NM_005733.1           KIF20A                       kinesin family member 20A                       −3.45           −2.21          NM_018186.2      C1orf112                  chromosome 1 open reading frame 112                  −2.47   −1.88
  NM_002263.2            KIFC1                       kinesin family member C1                        −3.36           −2.74          NM_001786.2        CDC2                 cell division cycle 2, G1 to S and G2 to M              −2.47   −2.63
  NM_006681.1             NMU                              neuromedin U                              −3.33           −3.15          NM_002105.2       H2AFX                        H2A histone family, member X                     −2.46   −2.86
  NM_014783.2          ARHGAP11A                 Rho GTPase activating protein 11A                   −3.33           −3.46          NM_018492.2        PBK                              PDZ binding kinase                          −2.46   −2.21
  NM_006176.1            NRGN                               neurogranin                              −3.29           −4.20          NM_198516.1      GALNTL4                    UDP-N-acetyl-alpha-D-galactosamine                  −2.46   −1.82
  NM_016095.1            GINS2                        GINS complex subunit 2                         −3.25           −4.51          NM_018685.2        ANLN                       anillin, actin binding protein                    −2.46   −2.44
  NM_018063.3            HELLS                      helicase, lymphoid-specific                      −3.24           −3.42          NM_002915.3        RFC3                replication factor C (activator 1) 3, 38kDa              −2.45   −2.59
  NM_057735.1            CCNE2                               cyclin E2                               −3.22           −3.24          NM_007370.3        RFC5               replication factor C (activator 1) 5, 36.5kDa             −2.43   −2.28
  NM_014750.3            DLG7                         discs, large homolog 7                         −3.21           −2.48         NM_001032290.1     PSRC1                     proline/serine-rich coiled-coil 1                   −2.43   −2.53
  NM_001168.2            BIRC5                  baculoviral IAP repeat-containing 5                  −3.18           −2.79          NM_000057.2        BLM                                Bloom syndrome                            −2.43   −3.28
  NM_001255.2            CDC20                    cell division cycle 20 homolog                     −3.12           −2.46          NM_012484.1        HMMR                   hyaluronan-mediated motility receptor                 −2.43   −1.82
  NM_001237.2            CCNA2                               cyclin A2                               −3.11           −3.01          NM_145701.1       CDCA4                      cell division cycle associated 4                   −2.43   −2.26
  NM_144508.3            CASC5                   cancer susceptibility candidate 5                   −3.09           −2.13          NM_024339.2       THOC6                           THO complex 6 homolog                         −2.41   −1.74
  NM_017611.2           SLC43A3                 solute carrier family 43, member 3                   −3.05           −2.60          NM_003258.2        TK1                              thymidine kinase 1                          −2.41   −3.74
  NM_018154.2            ASF1B               ASF1 anti-silencing function 1 homolog B                −3.03           −3.06          NM_182776.1        MCM7               minichromosome maintenance complex component 7            −2.39   −2.54
  NM_018410.3            HJURP                 Holliday junction recognition protein                 −3.02           −3.18          NM_178448.2      C9orf140                  chromosome 9 open reading frame 140                  −2.39   −2.34
  NM_004217.2            AURKB                            aurora kinase B                            −3.01           −3.19          NM_001067.2       TOP2A                    topoisomerase (DNA) II alpha 170kDa                  −2.39   −3.16
  NM_002692.2            POLE2          polymerase (DNA directed), epsilon 2 (p59 subunit)           −3.01           −3.00          NM_178014.2        TUBB                               tubulin, beta                             −2.37   −2.27
  NM_018101.2            CDCA8                   cell division cycle associated 8                    −2.97           −2.85          NM_018193.2       FANCI                  Fanconi anemia, complementation group I                −2.37   −2.52
  NM_002875.2            RAD51                             RAD51 homolog                             −2.95           −2.66          NM_206833.2       CTXN1                                 cortexin 1                              −2.36   −2.04
  NM_031299.3            CDCA3                   cell division cycle associated 3                    −2.94           −2.82          NM_031966.2       CCNB1                                 cyclin B1                               −2.36   −2.28
  NM_181803.1            UBE2C                   ubiquitin-conjugating enzyme E2C                    −2.91           −2.80          NM_005483.2       CHAF1A              chromatin assembly factor 1, subunit A (p150)             −2.36   −2.21
  NM_001100118.1         XRCC3             X-ray repair complementing defective repair 3             −2.90           −3.66          NM_005518.2       HMGCS2             3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2           −2.35   −2.88
  NM_025049.2            PIF1                   PIF1 5′-to-3′ DNA helicase homolog                   −2.90           −2.87          NM_019013.1       FAM64A                    family with sequence similarity 64                  −2.35   −3.13
  NM_030928.2            CDT1            chromatin licensing and DNA replication factor 1            −2.86           −2.76          NM_002129.2       HMGB2                         high-mobility group box 2                       −2.35   −2.18
  NM_016556.1           PSMC3IP                      PSMC3 interacting protein                       −2.85           −3.47         NM_001034194.1     EXOSC9                           exosome component 9                          −2.34   −1.69
  NM_182746.1            MCM4             minichromosome maintenance complex component 4             −2.84           −2.97          NM_031423.3        NUF2                NDC80 kinetochore complex component, homolog             −2.34   −2.48
  NM_016937.2            POLA1         polymerase (DNA directed), alpha 1, catalytic subunit         −2.84           −2.19          NM_002916.3        RFC4                replication factor C (activator 1) 4, 37kDa              −2.33   −2.36
  NM_007086.2            WDHD1              WD repeat and HMG-box DNA binding protein 1              −2.80           −2.53          NM_004111.4        FEN1                   flap structure-specific endonuclease 1                −2.33   −1.97
  NM_001761.1            CCNF                                cyclin F                                −2.80           −2.77          NM_145061.3      C13orf3                    chromosome 13 open reading frame 3                  −2.33   −2.53
  NM_012177.2            FBXO5                            F-box protein 5                            −2.78           −2.95         NM_001012413.1     SGOL1                              shugoshin-like 1                           −2.33   −2.85
  NM_018518.3            MCM10            minichromosome maintenance complex component 10            −2.78           −4.01          NM_207418.2       GCUD2                       gastric cancer up-regulated-2                     −2.32   −2.28
  NM_003579.2           RAD54L                              RAD54-like                               −2.76           −2.98          NM_199413.1        PRC1                     protein regulator of cytokinesis 1                  −2.32   −2.13
  NM_020242.1            KIF15                       kinesin family member 15                        −2.75           −3.00          NM_006461.3       SPAG5                         sperm associated antigen 5                      −2.31   −1.92
  NM_004336.2            BUB1          BUB1 budding uninhibited by benzimidazoles 1 homolog          −2.74           −2.47          NM_080668.2       CDCA5                      cell division cycle associated 5                   −2.29   −2.94
  NM_003384.2            VRK1                        vaccinia related kinase 1                       −2.73           −1.89          NM_006101.1       NDC80                               NDC80 homolog                             −2.29   −3.12
  NM_018454.5           NUSAP1              nucleolar and spindle associated protein 1               −2.72           −2.40         NM_001012507.1    C6orf173                  chromosome 6 open reading frame 173                  −2.29   −2.38
  NM_001034.1            RRM2                 ribonucleotide reductase M2 polypeptide                −2.72           −2.54          NM_002497.2        NEK2              NIMA (never in mitosis gene a)-related kinase 2            −2.29   −2.10
  NM_012112.4            TPX2                     microtubule-associated, homolog                    −2.72           −2.32          NM_024900.3       PHF17                           PHD finger protein 17                         −2.28   −1.67
  NM_152259.3          C15orf42                 chromosome 15 open reading frame 42                  −2.70           −3.44         NM_001040668.1    BCL2L12                               BCL2-like 12                             −2.28   −1.93
  NM_001042426.1         CENPA                         centromere protein A                          −2.70           −3.28          NM_014264.3        PLK4                             polo-like kinase 4                          −2.27   −1.97
  NM_012415.2           RAD54B                            RAD54 homolog B                            −2.69           −1.88          NM_022809.2       CDC25C                     cell division cycle 25 homolog C                   −2.27   −2.05
  NM_181471.1            RFC2               replication factor C (activator 1) 2, 40kDa              −2.69           −2.50          NM_152515.2       CKAP2L                  cytoskeleton associated protein 2-like                −2.26   −2.29
  NM_005480.2            TROAP                     trophinin associated protein                      −2.69           −2.49          NM_006026.2        H1FX                        H1 histone family, member X                      −2.24   −2.08
  NM_006845.2            KIF2C                       kinesin family member 2C                        −2.68           −2.81          NM_003276.1        TMPO                                thymopoietin                             −2.24   −1.95
  NM_022346.3            NCAPG                      non-SMC condensin I complex                      −2.68           −2.70          NM_018136.3        ASPM                       asp (abnormal spindle) homolog                    −2.23   −2.51
  NM_004260.2           RECQL4                          RecQ protein-like 4                          −2.68           −3.00          NM_016426.4       GTSE1                        G-2 and S-phase expressed 1                      −2.23   −2.44
  NM_003318.3             TTK                           TTK protein kinase                           −2.67           −2.40          NM_014875.1       KIF14                          kinesin family member 14                       −2.23   −2.12
  NM_030919.2           FAM83D             family with sequence similarity 83, member D              −2.66           −2.08          NM_014109.2       ATAD2                   ATPase family, AAA domain containing 2                −2.23   −2.21
  NM_001254.3            CDC6                      cell division cycle 6 homolog                     −2.66           −3.05          NM_003390.2        WEE1                                WEE1 homolog                             −2.22   −1.97
  NM_001034836.1         RDM1                              RAD52 motif 1                             −2.65           −2.65          NM_002388.3        MCM3               minichromosome maintenance complex component 3            −2.22   −2.45
  NM_004526.2            MCM2             minichromosome maintenance complex component 2             −2.65           −3.43          NM_005030.3        PLK1                             polo-like kinase 1                          −2.22   −2.37
  NM_004701.2            CCNB2                               cyclin B2                               −2.65           −2.52          NM_005375.2        MYB                 v-myb myeloblastosis viral oncogene homolog              −2.22   −2.01
  NM_032818.2          C9orf100                 chromosome 9 open reading frame 100                  −2.64           −2.30          NM_024789.3      TMEM180                        transmembrane protein 180                       −2.20   −1.63
  NM_006397.2          RNASEH2A                     ribonuclease H2, subunit A                       −2.64           −2.52         NM_001012716.1    C18orf56                  chromosome 18 open reading frame 56                  −2.20   −2.30
  NM_014736.4          KIAA0101                              KIAA0101                                −2.61           −3.47          NM_017760.5       NCAPG2                 non-SMC condensin II complex, subunit G2               −2.20   −2.11
  NM_004219.2            PTTG1                    pituitary tumor-transforming 1                     −2.61           −2.23          NM_005192.2       CDKN3                    cyclin-dependent kinase inhibitor 3                  −2.20   −1.98
  NM_182513.1            SPC24          SPC24, NDC80 kinetochore complex component, homolog          −2.61           −3.15          NM_006231.2        POLE                         polymerase (DNA directed)                       −2.19   −3.53
  NM_198948.1            NUDT1      nudix (nucleoside diphosphate linked moiety X)-type motif 1      −2.59           −3.09          NM_018124.3       RFWD3                     ring finger and WD repeat domain 3                  −2.19   −1.56
  NM_033286.2          C15orf23                 chromosome 15 open reading frame 23                  −2.58           −1.77          NM_006088.5       TUBB2C                             tubulin, beta 2C                           −2.19   −1.63
  NM_024053.3            CENPM                         centromere protein M                          −2.57           −3.45          NM_198434.1       AURKA                              aurora kinase A                            −2.18   −1.68
  NM_006479.3          RAD51AP1                     RAD51 associated protein 1                       −2.57           −2.54          NM_007280.1        OIP5                         Opa interacting protein 5                       −2.18   −2.34
  NM_006739.3            MCM5             minichromosome maintenance complex component 5             −2.56           −3.21          NM_014176.2       UBE2T                ubiquitin-conjugating enzyme E2T (putative).             −2.15   −2.01
  NM_203401.1            STMN1                       stathmin 1/oncoprotein 18                       −2.56           −2.32          NM_199420.3        POLQ                      polymerase (DNA directed), theta                   −2.14   −2.45
  NM_013277.2           RACGAP1                   Rac GTPase activating protein 1                    −2.55           −1.79          NM_001211.4       BUB1B         BUB1 budding uninhibited by benzimidazoles 1 homolog beta       −2.13   −2.23
  NM_001005413.1         ZWINT                            ZW10 interactor                            −2.55           −2.64         NM_001025248.1      DUT                         deoxyuridine triphosphatase                      −2.13   −2.36
  NM_004856.4            KIF23                       kinesin family member 23                        −2.54           −2.17          NM_031217.2       KIF18A                        kinesin family member 18A                       −2.13   −1.99
  NM_004523.2            KIF11                       kinesin family member 11                        −2.53           −2.12          NM_025108.2      C16orf59                  chromosome 16 open reading frame 59                  −2.12   −3.48
  NR_002734.1            PTTG3                    pituitary tumor-transforming 3                     −2.53           −2.43         NM_001042517.1     DIAPH3                           diaphanous homolog 3                         −2.12   −2.34
  NM_006027.3            EXO1                              exonuclease 1                             −2.52           −3.86          NM_017998.1      C9orf40                    chromosome 9 open reading frame 40                  −2.11   −1.85
  NM_016448.1             DTL                          denticleless homolog                          −2.51           −3.12          NM_052844.3       WDR34                            WD repeat domain 34                          −2.11   −2.71
  NM_022770.2            GINS3                 GINS complex subunit 3 (Psf3 homolog)                 −2.10           −1.65          NM_017918.3      CCDC109B                   coiled-coil domain containing 109B                  −1.84   −1.84
  NM_003503.2            CDC7                      cell division cycle 7 homolog                     −2.09           −1.97          NM_005782.2       THOC4                               THO complex 4                             −1.84   −1.63
  NM_001071.1            TYMS                         thymidylate synthetase                         −2.08           −3.41          NM_003035.2        STIL                        SCL/TAL1 interrupting locus                      −1.84   −1.95
  NM_005441.2           CHAF1B             chromatin assembly factor 1, subunit B (p60)              −2.08           −2.25          NM_005342.2       HMGB3                         high-mobility group box 3                       −1.83   −1.60
  NM_014865.2           NCAPD2                non-SMC condensin I complex, subunit D2                −2.07           −2.03          NM_018132.3       CENPQ                            centromere protein Q                         −1.83   −2.10
  NM_001798.2            CDK2                        cyclin-dependent kinase 2                       −2.07           −1.88          NM_024516.2      C16orf53                  chromosome 16 open reading frame 53                  −1.81   −1.86
  NM_022720.5            DGCR8               DiGeorge syndrome critical region gene 8                −2.07           −1.57          NM_015895.3        GMNN                     geminin, DNA replication inhibitor                  −1.81   −1.87
  NM_145018.2          C11orf82                 chromosome 11 open reading frame 82                  −2.06           −2.28          NM_002689.2       POLA2             polymerase (DNA directed), alpha 2 (70kD subunit)           −1.81   −2.11
  NM_016195.2           KIF20B                       kinesin family member 20B                       −2.06           −1.63          NM_000154.1       GALK1                              galactokinase 1                            −1.80   −1.84
  NM_001008393.1       LOC201725                       hypothetical protein                          −2.05           −1.98          NM_004499.3      HNRNPAB               heterogeneous nuclear ribonucleoprotein A/B              −1.80   −2.31
  NM_000465.1            BARD1                    BRCA1 associated RING domain 1                     −2.05           −2.42          NM_024656.2      GLT25D1                glycosyltransferase 25 domain containing 1              −1.80   −1.62
  NM_003173.2           SUV39H1               suppressor of variegation 3-9 homolog 1                −2.05           −1.89          NM_199250.1      C19orf48                  chromosome 19 open reading frame 48                  −1.79   −1.83
  NM_015426.2           WDR51A                         WD repeat domain 51A                          −2.05           −1.60          NM_153329.2      ALDH16A1              aldehyde dehydrogenase 16 family, member A1              −1.79   −1.98
  NM_020342.1          SLC39A10                      solute carrier family 39                        −2.05           −3.15          NM_032637.2        SKP2                 S-phase kinase-associated protein 2 (p45)               −1.79   −2.00
  NM_144999.2           LRRC45                   leucine rich repeat containing 45                   −2.04           −3.33          NM_006191.2       PA2G4                    proliferation-associated 2G4, 38kDa                  −1.78   −1.84
  NM_000946.2            PRIM1                  primase, DNA, polypeptide 1 (49kDa)                  −2.04           −2.29         NM_001033580.1     MYO19                                 myosin XIX                              −1.78   −3.61
  NM_016183.3            MRTO4                          turnover 4 homolog                           −2.04           −1.68          NM_017915.2      C12orf48                  chromosome 12 open reading frame 48                  −1.78   −1.92
  NM_017518.5           UCHL5IP                      UCHL5 interacting protein                       −2.04           −1.75          NM_003362.2        UNG                            uracil-DNA glycosylase                        −1.76   −1.55
  NM_020394.2           ZNF695                        zinc finger protein 695                        −2.03           −2.78          NM_014985.2       CEP152                        centrosomal protein 152kDa                      −1.75   −2.37
  NM_203394.2            E2F7                       E2F transcription factor 7                       −2.02           −2.03          NM_001333.2       CTSL2                                cathepsin L2                             −1.75   −1.70
  NM_173529.3          C18orf54                 chromosome 18 open reading frame 54                  −2.02           −1.99          NM_016310.2       POLR3K       polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa      −1.75   −1.59
  NM_000156.4            GAMT                  guanidinoacetate N-methyltransferase                  −2.02           −1.64          NM_006406.1       PRDX4                              peroxiredoxin 4                            −1.74   −1.93
  NM_007299.2            BRCA1                     breast cancer 1, early onset                      −2.02           −2.11          NM_005484.2       PARP2               poly (ADP-ribose) polymerase family, member 2             −1.74   −1.53
  NM_014641.1            MDC1                   mediator of DNA damage checkpoint 1                  −2.01           −1.57         NM_001039091.1     PRPS2                 phosphoribosyl pyrophosphate synthetase 2               −1.73   −1.60
  NM_032485.4            MCM8             minichromosome maintenance complex component 8             −2.01           −3.18          NM_015703.3       RRP7A                    ribosomal RNA processing 7 homolog A                 −1.73   −1.71
  NM_024660.2           TMEM149                      transmembrane protein 149                       −2.01           −2.07          NM_015032.1       PDS5B             PDS5, regulator of cohesion maintenance, homolog B          −1.73   −1.78
  NM_015414.2            RPL36                         ribosomal protein L36                         −2.00           −2.40          NM_000992.2       RPL29                           ribosomal protein L29                         −1.73   −2.53
  NM_021734.3          SLC25A19                 solute carrier family 25, member 19                  −2.00           −1.67          NM_173608.1      C14orf80                  chromosome 14 open reading frame 80                  −1.72   −1.73
  NM_003504.3           CDC45L                   CDC45 cell division cycle 45-like                   −2.00           −2.84         NM_001042550.1      SMC2                  structural maintenance of chromosomes 2                −1.72   −1.92
  NM_014708.3            KNTC1                       kinetochore associated 1                        −1.99           −1.86          NM_014285.4       EXOSC2                           exosome component 2                          −1.72   −1.70
  NM_018131.3            CEP55                       centrosomal protein 55kDa                       −1.98           −2.01          NM_138961.1        ESAM                     endothelial cell adhesion molecule                  −1.71   −2.21
  NM_007243.1             NRM                                  nurim                                 −1.98           −2.22          NM_145159.1        JAG2                                  jagged 2                               −1.70   −1.89
  NM_003517.2          HIST2H2AC                      histone cluster 2, H2ac                        −1.98           −2.54          NM_006392.2       NOL5A               nucleolar protein 5A (56kDa with KKE/D repeat)            −1.69   −1.70
  NM_001002800.1         SMC4                 structural maintenance of chromosomes 4                −1.98           −1.94          NM_033661.3        WDR4                             WD repeat domain 4                          −1.69   −1.84
  NM_001033505.1         CSTF3       cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77kD        −1.97           −1.96          NM_032358.2       CCDC77                     coiled-coil domain containing 77                   −1.68   −1.54
  NM_181716.2            PRR6                             proline rich 6                             −1.96           −1.85          NM_018693.2       FBXO11                             F-box protein 11                           −1.68   −1.93
  NM_018663.1            PXMP2                 peroxisomal membrane protein 2, 22kDa                 −1.96           −2.02          NM_001026.3       RPS24                           ribosomal protein S24                         −1.68   −1.94
  NM_005915.4            MCM6             minichromosome maintenance complex component 6             −1.96           −2.25          NM_016292.1       TRAP1                     TNF receptor-associated protein 1                   −1.67   −1.51
  NM_005189.1            CBX2                           chromobox homolog 2                          −1.96           −1.68          NM_017613.2       DONSON                        downstream neighbor of SON                      −1.66   −1.61
  NM_001379.1            DNMT1                 DNA (cytosine-5-)-methyltransferase 1                 −1.96           −1.84          NM_006047.4       RBM12                        RNA binding motif protein 12                     −1.66   −1.91
  NM_001002018.1        HCFC1R1          host cell factor C1 regulator 1 (XPO1 dependent)            −1.96           −1.79          NM_012140.3      SLC25A10    solute carrier family 25 (dicarboxylate transporter), member 10    −1.66   −1.55
  NM_000234.1            LIG1                      ligase I, DNA, ATP-dependent                      −1.96           −2.81         NM_001025238.1     TSPAN4                              tetraspanin 4                             −1.66   −1.94
  NM_138443.2            CCDC5         coiled-coil domain containing 5 (spindle associated)          −1.95           −1.68         NM_001008735.1     HMG1L1      high-mobility group (nonhistone chromosomal) protein 1-like 1     −1.66   −1.62
  NM_020315.4            PDXP             pyridoxal (pyridoxine, vitamin B6) phosphatase             −1.95           −2.04          NM_005956.2       MTHFD1        methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1      −1.65   −1.69
  NM_032117.2            MND1                   meiotic nuclear divisions 1 homolog                  −1.95           −2.63          NM_145014.1       HYLS1                          hydrolethalus syndrome 1                       −1.65   −1.62
  NM_194255.1           SLC19A1       solute carrier family 19 (folate transporter), member 1        −1.95           −1.93          NM_004309.3      ARHGDIA                Rho GDP dissociation inhibitor (GDI) alpha              −1.64   −1.75
  NM_058216.1           RAD51C                            RAD51 homolog C                            −1.94           −2.13          NM_182649.1        PCNA                     proliferating cell nuclear antigen                  −1.63   −1.99
  NM_018725.3           IL17RB                       interleukin 17 receptor B                       −1.94           −2.25          NM_032118.2       WDR54                            WD repeat domain 54                          −1.63   −1.77
  NM_024844.3            NUP85                           nucleoporin 85kDa                           −1.93           −1.53          NM_015697.6        COQ2                            coenzyme Q2 homolog                          −1.63   −1.85
  NM_015190.3           DNAJC9              DnaJ (Hsp40) homolog, subfamily C, member 9              −1.93           −1.64          NM_032982.2       CASP2                                 caspase 2                               −1.63   −1.67
  NM_004237.2           TRIP13                thyroid hormone receptor interactor 13                 −1.93           −2.23         NM_001042762.1     FIGNL1                             fidgetin-like 1                            −1.63   −1.85
  NM_000179.1            MSH6                             mutS homolog 6                             −1.93           −1.83         NM_001100417.1      UBR7       ubiquitin protein ligase E3 component n-recognin 7 (putative)     −1.61   −1.64
  NM_001009936.1         PHF19                         PHD finger protein 19                         −1.93           −2.42          NM_003146.2       SSRP1                  structure specific recognition protein 1               −1.60   −1.66
  NM_003609.2           HIRIP3                      HIRA interacting protein 3                       −1.92           −2.01          NM_152308.1      C16orf75                  chromosome 16 open reading frame 75                  −1.60   −1.99
  NM_022145.3            CENPK                         centromere protein K                          −1.92           −2.25         NM_001024662.1      RPL6                            ribosomal protein L6                         −1.60   −1.56
  NM_022908.1           NT5DC2                  5′-nucleotidase domain containing 2                  −1.92           −1.81          NM_182620.3       FAM33A               family with sequence similarity 33, member A             −1.59   −2.17
  NM_006342.1            TACC3         transforming, acidic coiled-coil containing protein 3         −1.92           −2.27          NM_033120.2        NKD2                          naked cuticle homolog 2                        −1.59   −1.65
  NM_001080450.1       KIAA1553                              KIAA1553                                −1.92           −1.65          NM_003472.2        DEK                          DEK oncogene (DNA binding)                      −1.58   −1.91
  NM_001018115.1        FANCD2               Fanconi anemia, complementation group D2                −1.92           −2.39          NM_032015.3       RNF26                           ring finger protein 26                        −1.58   −1.70
  NM_001033.2            RRM1                 ribonucleotide reductase M1 polypeptide                −1.92           −1.87          NM_018455.3       CENPN                            centromere protein N                         −1.57   −2.01
  NM_001078174.1        SLC29A1         solute carrier family 29 (nucleoside transporters)           −1.91           −2.19          NM_003091.3       SNRPB           small nuclear ribonucleoprotein polypeptides B and B1         −1.56   −1.52
  NM_153485.1           NUP155                          nucleoporin 155kDa                           −1.91           −1.65          NM_003863.2        DPM2            dolichyl-phosphate mannosyltransferase polypeptide 2         −1.56   −1.77
  NM_002482.2            NASP          nuclear autoantigenic sperm protein (histone-binding)         −1.91           −1.96          NM_017916.1       PIH1D1                         PIH1 domain containing 1                       −1.55   −1.97
  NM_176880.4           NR2C2AP               nuclear receptor 2C2-associated protein                −1.90           −1.87          NM_020810.1       TRMT5                      tRNA methyltransferase 5 homolog                   −1.55   −1.54
  NM_021953.2            FOXM1                            forkhead box M1                            −1.90           −2.28          NM_058219.2       EXOSC6                           exosome component 6                          −1.55   −1.65
  NM_015721.2           GEMIN4             gem (nuclear organelle) associated protein 4              −1.90           −1.54          NM_002882.2       RANBP1                          RAN binding protein 1                         −1.54   −1.88
  NM_018188.2           ATAD3A                ATPase family, AAA domain containing 3A                −1.89           −1.70          NM_007111.3       TFDP1                         transcription factor Dp-1                       −1.54   −1.51
  NM_145060.3          C18orf24                 chromosome 18 open reading frame 24                  −1.89           −2.45          NM_021709.1        SIVA                        CD27-binding (Siva) protein                      −1.54   −1.71
  NM_018365.1            MNS1                  meiosis-specific nuclear structural 1                 −1.89           −2.12          NM_015140.2       TTLL12              tubulin tyrosine ligase-like family, member 12            −1.53   −1.61
  NM_012310.3            KIF4A                       kinesin family member 4A                        −1.89           −2.38          NM_022044.2       SDF2L1                   stromal cell-derived factor 2-like 1                 −1.53   −1.70
  NM_015261.2           NCAPD3               non-SMC condensin II complex, subunit D3                −1.88           −1.88          NM_002346.1        LY6E                   lymphocyte antigen 6 complex, locus E                 −1.52   −1.56
  NM_013296.3            GPSM2                   G-protein signalling modulator 2                    −1.87           −1.63          NM_022490.1       POLR1E                 polymerase (RNA) I polypeptide E, 53kDa                −1.52   −1.77
  NM_002691.1            POLD1         polymerase (DNA directed), delta 1, catalytic subunit         −1.87           −2.22          NM_032799.4      ZDHHC12                   zinc finger, DHHC-type containing 12                 −1.51   −1.64
  NM_203467.1            PPIL5             peptidylprolyl isomerase (cyclophilin)-like 5             −1.87           −1.79         NM_001017980.2   LOC203547                          hypothetical protein                         −1.51   −1.54
  NM_015201.3            BOP1                        block of proliferation 1                        −1.87           −2.29          NM_003801.3       GPAA1      glycosylphosphatidylinositol anchor attachment protein 1 homolog   −1.51   −1.89
  NM_018353.3          C14orf106               chromosome 14 open reading frame 106                  −1.86           −1.54          NM_016594.1       FKBP11                     FK506 binding protein 11, 19 kDa                   −1.50   −1.94
  NM_080626.5           BRI3BP                         BRI3 binding protein                          −1.84           −1.72          NM_022754.4       SFXN1                               sideroflexin 1                            −1.50   −1.88

Modulation of canonical signaling pathways following inhibition of HH signaling {#s2c}
-------------------------------------------------------------------------------

Genes with significant changes in expression following GANT61 treatment were assigned to different canonical signaling pathways and subjected to Ingenuity Pathway Analysis (IPA), where the resulting 1,368 DEGs in HT29 and 1,002 DEGs in GC3/c1 were mapped to networks defined by the IPA database ([Figure 3](#pone-0013054-g003){ref-type="fig"}). For the mapped DEGs including both up- and down- regulated genes, the 15 most significantly altered canonical pathways in HT29 demonstrated --log(p-value) ranging from 2.045 to 9.025, and in GC3/c1 from 2.32 to 7.509. Of the 15 pathways involving genes significantly down-regulated, 12 were common to both cell lines. The 3 common pathways with the greatest differential down-regulated expression include genes involved in the DNA damage response, cell cycle checkpoint control, and mitosis. Other pathways down-regulated involved the G1/S and G2/M DNA damage checkpoints, DNA precursor metabolism, and cell signaling involving different pathways including those involved in cancers, which also demonstrate 3 signatures unique to either HT29 or GC3/c1 ([Figure 3](#pone-0013054-g003){ref-type="fig"}). Of the 15 pathways involving genes that are the most significantly up-regulated, 8 are common to both HT29 and GC3/c1, and 7 represent unique pathways for each cell line, demonstrating more diversity in patterns of up-regulated gene expression ([Figure 3](#pone-0013054-g003){ref-type="fig"}). The up-regulated pathways common to both cell lines include the metabolism-related such as steroids, pyruvate, glycolysis glutathione, or glycerolipid, and not directly related to the control of cellular proliferation.

![The top 15 canonical signaling pathways influenced by inhibition of GLI1/GLI2 function in HT29 and GC3/c1 cells.\
The top 15 canonical signaling pathways, determined by IPA, that were significantly up-regulated or down-regulated by GANT61 treatment in HT29 and GC3/c1 cells, are shown. The 1,368 DEGs in HT29 and 1,002 DEGs in GC3/c1 were mapped to the IPA- defined network. The significance p-values that determine the probability that the association between the genes in the dataset and the canonical pathway is by chance alone were calculated by Fisher\'s exact test, and are expressed as --log (p-value). **A**. Pathways with enriched down-regulated genes. **B**. Pathways with enriched up-regulated genes. Blue: Pathways common to both HT29 and GC3/c1. Red: Pathways unique to either HT29 or GC3/c1. Yellow squares: Ratio of the number of DEGs that map to a specific canonical pathway divided by total number of genes that make up that pathway.](pone.0013054.g003){#pone-0013054-g003}

Genes that demonstrate differential fold change patterns in GANT61-treated HT29 and GC3/c1 cells {#s2d}
------------------------------------------------------------------------------------------------

Fold change patterns of most highly DEGs in HT29 and GC3/c1 were selected, analyzed and displayed in a heat map to evaluate and compare similarity and differences in differential expression between the two cell lines treated with GANT61 ([Figure 4](#pone-0013054-g004){ref-type="fig"}). In addition to genes with diverse functions that are not directly related to HH-dependent proliferation, up-regulated genes that influence the G1/S transition and subsequent cell cycle progression, and that are common to both cell lines, include CDKN1A, and the DNA-damage-inducible transcripts 3 and 4 (DDIT3 and DDIT4). A considerably greater number of genes involved in cellular proliferation and cell cycle transition through the G1/S boundary, S-phase progression, and the G2/M transition, were significantly down-regulated in expression, and common to both cell lines. These include CDC6 (involved at G1/S), three genes that drive entry into and passage through S-phase (CCNE2, E2F2) and G2 (CCNA2), genes involved in DNA replication and repair (TYMS, POLE, TOP2A, TK1, POLE2), and two genes that regulate mitosis (AURKB, CDC20; [Figure 4](#pone-0013054-g004){ref-type="fig"}, asterisks).

![Heat map showing fold change patterns of most highly DEGs in GANT61-treated human colon carcinoma cell lines.\
The heat map was generated in Matlab (Mathworks), and compares fold change patterns of the most highly DEGs in HT29 and GC3/c1 cells after GANT61 treatment. The most highly DEGs demonstrated a differential expression p-value of p\<0.001 between vehicle control (0.2% DMSO) and GANT61-treated cells. Left panel (red): up-regulated genes. Right panel (green): down-regulated genes. Genes denoted with asterisks define those genes with specific roles in G1/S transition, S-phase progression, DNA replication or repair, or regulation of the G2- or M- phase transitions. Fold changes of all down-regulated DEGs and all but one up-regulated DEG are ≤8 (central color spectrum bar).](pone.0013054.g004){#pone-0013054-g004}

Of the 296 up-regulated genes, in addition to the genes comparably represented in the heat map that include DDIT3 (GADD153) and DDIT4 (REDD1), additional novel DNA damage-inducible transcripts were also identified and include DDIT2 (GADD45G), PPP1R15A (GADD34) and ATF3 ([Table 1](#pone-0013054-t001){ref-type="table"}). TP53INP1, which can regulate cell cycle arrest, and TP53INP2, identified in cell death responses, were also up-regulated. Of the 309 genes significantly down-regulated in response to GANT61, novel genes identified include KIAA0101 (p15\[PAF\]), Replication Factor C variants 2, 3, 4, 5, CDT1, the E2F transcription factors CDCA4 and TFDP1, MDC1, PCNA, FANCD2, and the genes involved in DNA repair, RAD51C (XRCC3), RAD54B, RAD51 and HELLS ([Table 2](#pone-0013054-t002){ref-type="table"}).

Differentially expressed genes involved in the G1/S and G2/M transitions {#s2e}
------------------------------------------------------------------------

To further evaluate the genes involved in control of cell cycle progression in human colon carcinoma cells following GANT61 treatment, 10 genes involved in the G1/S or G2/M transitions, identified by IPA, were selected for further examination. Genes required at the G1/S boundary for G1/S transition, or for the induction of a G1/S checkpoint following cytostatic signals, include the two cyclin-dependent kinase inhibitors, p21^Cip1^ (CDKN1A) and p15^Ink4B^ (CDKN2B), which were up-regulated by 5.2- and 3.1- fold, 24 hr after GANT61 administration ([Table 3](#pone-0013054-t003){ref-type="table"}). Additional genes required for the G1/S transition that were down-regulated include the E2 transcription factor E2F2 (-4.2-fold), and other critical genes that were down-regulated by 2.1- to 3.2- fold, include CYCLIN E (CCNE2), CDK2 and CDC25A. At G2/M, GANT61 induced down-regulated expression of CCNA2 (CYCLIN A2), CYCLIN B1 (CCNB1), CYCLIN B2 (CCNB2), CDK1 (CDC2), and CDC25C by 2.3- to 3.1- fold ([Table 3](#pone-0013054-t003){ref-type="table"}).

10.1371/journal.pone.0013054.t003

###### Gene expression changes from cDNA arrays at G1/S and G2/M.

![](pone.0013054.t003){#pone-0013054-t003-3}

  Cell Cycle Phase    Accession Number   Gene Symbol                       Gene Name                       Fold Change  
  ------------------ ------------------ ------------- --------------------------------------------------- ------------- -------
  G1/S                  NM_000389.2        CDKN1A      cyclin-dependent kinase inhibitor 1A (p21^Cip1^)       +5.21      +2.02
                        NM_078487.2        CDKN2B      cyclin-dependent kinase inhibitor 2B (p15^Ink4b^)      +3.13      +2.13
                        NM_004091.2         E2F2                  E2F transcription factor 2                  −4.24      −2.26
                        NM_057735.1         CCNE2                          cyclin E2                          −3.22      −3.24
                        NM_001789.2        CDC25A              cell division cycle 25 homolog A               −2.50      −2.45
                        NM_001798.2         CDK2                   cyclin−dependent kinase 2                  −2.07      −1.88
  G2/M                  NM_001237.2         CCNA2                          cyclin A2                          −3.11      −3.01
                        NM_004701.2         CCNB2                          cyclin B2                          −2.65      −2.52
                        NM_001786.2         CDK1                   cyclin-dependent kinase 1                  −2.47      −2.63
                        NM_031966.2         CCNB1                          cyclin B1                          −2.36      −2.28
                        NM_022809.2        CDC25C              cell division cycle 25 homolog C               −2.27      −2.05

To determine the robustness of cDNA microarray gene expression profiling following treatment of HT29 and GC3/c1 cells with GANT61 (20 µM) for 24 hr, qRT-PCR was employed to determine changes in expression of the selected group of 10 DEGs determined from the cDNA microarrays. The genes involved and primers synthesized are shown in [Table 4](#pone-0013054-t004){ref-type="table"}. qRT-PCR was performed on cDNA generated using total RNA independently isolated from GANT61-treated HT29 and GC3/c1 cells for 0 hr, 16 hr, 24 hr, 38 hr and 48 hr after treatment. GAPDH was used to normalize all qRT-PCR data. Genes determined by qRT-PCR included the expression of E2F2, CCNE2, CDC25A and CDK2 at G1/S, which were down-regulated, up-regulation of CDKN1A and CDKN2B at G1/S, and down-regulation of CCNA2, CDC25C, CCNB2, and CDK1 at G2/M ([Figure 5](#pone-0013054-g005){ref-type="fig"}). The up-regulated or down-regulated changes in gene expression following GANT61 treatment and determined by cDNA microarray profiling, were confirmed by qRT-PCR ([Figure 5](#pone-0013054-g005){ref-type="fig"}).

![Selected DEGs from cDNA array gene expression profiling analyzed by qRT- PCR in HT29 (A) or GC3/c1 (B).\
Cells were treated with vehicle alone (0.2% DMSO) or GANT61 (20 µM) for 16 hr, 24 hr, 38 hr, or 48 hr. Total RNA was extracted and qRT-PCR was performed as described in [Materials and Methods](#s4){ref-type="sec"} using the primer sets listed in [Table 2](#pone-0013054-t002){ref-type="table"}. Data represent the mean±SD of 4 determinations, and GAPDH was used to normalize the relative mRNA levels.](pone.0013054.g005){#pone-0013054-g005}

10.1371/journal.pone.0013054.t004

###### Sequences of primers used in quantitative Real-Time PCR.

![](pone.0013054.t004){#pone-0013054-t004-4}

  Accession \#    Gene Symbol   Strand            Primer Sequence            Product Size (bp)
  -------------- ------------- -------- ----------------------------------- -------------------
  NM_078487.2       CDKN2B       Plus       5′-TCTCCGTTGGCCGGAGGTCA-3′              95
                                Minus       5′-TGGCAGGGTCTGCGCAGTTG-3′      
  NM_004701.2        CCNB2       Plus       5′-CTAACGGCGCCTCGTACGCT-3′              54
                                Minus       5′-CAGGGAGGGACGCGGACTGA-3′      
  NM_057749.1        CCNE2       Plus       5′-GAGCGGTAGCTGGTCTGGCG-3′              94
                                Minus       5′-GGGCTGGGGCTGCTGCTTAG-3′      
  NM_001789.2       CDC25A       Plus       5′-CGTGGCTGCCTGCACTCTCA-3′              159
                                Minus       5′-GGCTGTCACAGGTGACTGGGG-3′     
  NM_001798.3        CDK2        Plus      5′-TTTGCTGAGATGGTGACTCGCCG-3′            159
                                Minus       5′-CCGGGCCCACTTGGGGAAAC-3′      
  NM_004091.2        E2F2        Plus       5′-CCGGCAGAAGCTGTGTGGGG-3′              97
                                Minus       5′-GGCCTCCCTAGGCCCAGCTT-3′      
  NM_001237.3        CCNA2       Plus       5′-AAAAGGCAGCGCCCGTCCAA-3′              89
                                Minus       5′-CTGCTGCTGCGCTAGACCCC-3′      
  NM_005631.3       CDKN1A       Plus       5′-CTGCGCCAGCTGAGGTGTGA-3′              189
                                Minus       5′-GCTGCTCGCTGTCCACTGGG-3′      
  NM_022809.2       CDC25C       Plus    5′-GTGCATTTAGCTGGGATGACAATGGAA-3′          189
                                Minus      5′-GGCCACTTCTGCTCACCTTTGC-3′     
  NM_001786.2        CDK1        Plus      5′-ACTGGCTGATTTTGGCCTTGCC-3′             118
                                Minus     5′-TGAGTAACGAGCTGACCCCAGCAA-3′    
  NM_005269          GLI1        Plus        5′GCCCAGACAGAGGCCCACTC-3′              547
                                Minus        5′CTGCAGCCATCCCAACGGCA-3′      
  NM_005270          GLI2        Plus        5′-CACCGCTGCTCAAAGAGAA-3′              227
                                Minus        5′-TCTCCACGCCACTGTCATT-3′      
  NM_000264          PTCH1       Plus        5′-CCACAGAAGCGCTCCTACA-3′              214
                                Minus        5′-CTGTAATTTCGCCCCTTCC-3′      

Discussion {#s3}
==========

The HH signaling pathway is activated in a variety of human cancers following mutations in genes that regulate canonical HH signaling, including the receptor PTC, and the HH signaling molecule, SMO, and can also be activated via transcriptional up-regulation of the HH ligands (reviewed in [@pone.0013054-Katoh1]). This pathway is becoming of increasing importance due to gaining insight into its prominent role in many developmental processes, and in the maintenance of the malignant phenotype in a wide variety of human cancers, whose growth has been found to be prevented by selective inhibition of constitutive HH pathway activity [@pone.0013054-Kasper2], [@pone.0013054-Ingham1], [@pone.0013054-RuiziAltaba3]. Tumors of the brain, prostate, skin, pancreas, and kidney have demonstrated the requirement for HH-GLI signaling, and have responded to inhibition of the HH signaling target molecule SMO by cyclopamine or SMOshRNA [@pone.0013054-RuiziAltaba1], [@pone.0013054-Sanchez1], [@pone.0013054-Stecca1], [@pone.0013054-Feldmann1], [@pone.0013054-Sarangi1], [@pone.0013054-Dormoy1].

The transcriptional activators in HH signaling comprise members of the GLI family of transcription factors, GLI1 and GLI2, which have both distinct as well as overlapping functions [@pone.0013054-Eichberger1]. Activation of the GLI proteins is an intricate process that involves modifications and interactions of a number of positive and negative pathway regulators and is not fully understood [@pone.0013054-Lum1], [@pone.0013054-Kasper2], [@pone.0013054-Ingham1]. Target genes regulated by the HH signaling pathway differ between tissues and cell types, as well as being influenced by the presence or absence of regulatory factors co-expressed with GLI proteins that eventually determine the transcriptional programs activated by HH signaling [@pone.0013054-Kasper1], [@pone.0013054-Ingham2]. Thus, oncogenic signaling pathways converge on canonical HH signaling at the level of the GLI transcription factors and additionally on target genes downstream of GLI1 and GLI2 to further drive the HH signaling pathway in cellular survival in malignancies [@pone.0013054-Kasper1], [@pone.0013054-Yoon1], [@pone.0013054-Stecca1], [@pone.0013054-Riobo1], [@pone.0013054-Riobo2], [@pone.0013054-Schnidar1]. The HH signaling phenotype is therefore significantly influenced and ultimately determined by the co-expression of additional regulatory factors, and hence by the cellular context of gene expression.

HH signaling plays a role in the differentiation program of normal intestinal villi [@pone.0013054-Alinger1], [@pone.0013054-vandenBrink1], [@pone.0013054-Varnat3], and it has been suggested recently that human colon cancer epithelial cells display a HH-GLI signaling axis in the process of carcinogenesis [@pone.0013054-Yoshikawa1], [@pone.0013054-Bian1]. Expression of HH-GLI pathway components was consistently demonstrated in an analysis of 40 primary human colon carcinomas and tumors metastatic to the liver [@pone.0013054-Varnat2], consistent with findings of previous investigators [@pone.0013054-Bian1], [@pone.0013054-Monzo1], [@pone.0013054-Oniscu1]. Thus, using qRT-PCR, the expression of GLI1, PTCH1, GLI2 and SHH was determined in all human colon carcinomas examined. The requirement for both GLI1 and GLI2 for sustained proliferation and survival of human colon carcinoma cell lines in vitro, including HT29, was demonstrated using siRNA technology [@pone.0013054-Varnat2]. In addition, knockdown of SMO by SMOshRNA prevented the growth of HT29 cells in SCID mice, while wt HT29 subcutaneous xenografts responded to cyclopamine by reduction in tumor volume [@pone.0013054-Varnat2]. Thus, canonical activation of GLI1 and GLI2 via SMO is important for the survival and proliferation of human colon carcinoma cells in vivo.

In the current study, the function of both GLI1 and GLI2 downstream of SMO was inhibited in the presence of GANT61, a small molecule inhibitor that was identified from a cell-based screen to specifically inhibit GLI1-mediated transcription, but that also inhibited the function of GLI2 [@pone.0013054-Lauth1]. This agent was selected to specifically inhibit the final arbiters of HH signaling, the GLI transcription factors, in elucidation of the downstream target genes that determine HH-dependent proliferation in human colon carcinoma cells. Two cell lines, well characterized in our laboratories, HT29 and GC3/c1, were treated with GANT61 (20 µM) for 24 hr, and the expression of GLI1, GLI2 and PTCH1 mRNA was down-regulated. Further, the effects on cellular proliferation as determined by the distribution of cells within the cell cycle and flow cytometric analysis demonstrated accumulation of cells in G1 following treatment, with a concomitant decrease of cells from the G2/M compartment, and in the case of HT29, also from S-phase, suggesting the induction of a G1/S checkpoint.

HT29 and GC3/c1 cells were subsequently treated with GANT61 (20 µM) for 24 hr, RNA was extracted, and changes in gene expression were determined by Illumina cDNA microarray profiling. Following statistical analyses, 1,368 genes in HT29 and 1,002 genes in GC3/c1, were determined to be significantly modulated by GANT61 treatment (FC\>1.5; p\<0.001). For genes that were up-regulated in expression, 296 genes were common to both cell lines, and for down-regulated genes, 309 genes were common to both cell lines. The blockade of cells at the G1/S boundary is evidenced by up-regulated expression of p21^Cip1^ and p15^Ink4b^ that in part regulate the G1/S transition. p15^Ink4b^ is a member of the Ink4 family of CDK inhibitors, is induced in response to cytostatic signals [@pone.0013054-Choi1], [@pone.0013054-Koyama1], and complexes with CYCLIN D/CDK4 or CYCLIN D/CDK6 to mediate G1-phase arrest at the G1/S transition in certain systems [@pone.0013054-McDonald1], [@pone.0013054-Choi1]. p21^Cip1^ can bind a broad range of cyclin-CDK complexes, with a preference for those containing CDK2 (reviewed in [@pone.0013054-Harper1], [@pone.0013054-Gartel1], and during a normal cell cycle, facilitates active cyclin-CDK complex formation to promote cell proliferation. However when overexpressed, p21^Cip1^ forms an inhibitory complex with CYCLIN E/CDK2, leading to G1- and consequently S- phase arrest, thereby forming the G1/S checkpoint [@pone.0013054-Niculescu1], [@pone.0013054-Ogryzko1]. The scheduled timing of expression of CYCLINS E, A and B that drive cell cycle progression, is reflected in the major changes in the phases of the cell cycle. CYCLIN E is expressed at maximal levels in cells undergoing the G1 to S transition, declining during S-phase progression, such that G2/M cells are CYCLIN E-negative (reviewed in [@pone.0013054-McDonald1]). CYCLIN A is expressed in late G1, demonstrates pronounced expression during S-phase, and increases as the cells advance towards G2, with degradation in early mitosis; B type cyclins begin to be expressed in late S-phase, and drive the cells though G2- and M- phases of the cell cycle [@pone.0013054-McDonald1]. CDK2 controls the G1/S transition by complexing with CYCLIN E, and is activated by CDC25A, which dephosphorylates CDK2 [@pone.0013054-Sandhu1]. CDC2 controls cellular entry into mitosis at the G2/M transition, thereby forming complexes with CYCLINS A and B, is activated by CDC25C, and is down-regulated in late M-phase [@pone.0013054-Stark1]. All of these genes are down-regulated in expression in response to the inhibition of GLI1/GLI2 function ([Table 2](#pone-0013054-t002){ref-type="table"}). Thus, signals elicited to promote cellular accumulation at G1/S lead to the repression of genes that regulate further cell cycle progression, and p21^Cip1^ expression has been shown to deplete the expression of genes that regulate DNA replication and repair, and mitosis [@pone.0013054-Abbas1], [@pone.0013054-Chang1], [@pone.0013054-Chang2]. In the current study these genes include CDC6 (active at the G1/S transition and essential for the initiation of DNA replication), TYMS, TOP2A, TK1, POLE and POLE2 (S-phase), and AURKB and CDC20 (mitosis [@pone.0013054-Keen1], [@pone.0013054-Ge1]), determined by heat map analysis. A schematic representation of the genes involved in GANT61-induced inhibition of cell cycle progression at G1/S, S-phase progression, and regulation during G2- and M-phases, identified from cDNA microarrays, heat map analysis, and by qRT-PCR, is shown in [Figure 6](#pone-0013054-g006){ref-type="fig"}, and involves 5 of the 12 common signaling pathways determined by IPA analysis.

![Schematic representation of genes involved in GANT61-induced inhibition of cell cycle progression.\
From cDNA microarray, heat map, and qRT-PCR analyses, genes involved at different phases of the cell cycle including the G1/S transition, and progression through S- G2- and M- phases, are shown. The genes identified include CDK inhibitors, members of the CDK and CDC families, cyclins, genes involved in DNA replication and repair, and genes that regulate the mitotic spindle, and involve 5 of the 12 common signaling pathways determined by IPA analysis. Red: Up-regulated genes. Green: Down-regulated genes. Light shade→dark shade, increasing differential expression.](pone.0013054.g006){#pone-0013054-g006}

Comprehensive cDNA microarray gene profiling analysis of genes that determine the HH signaling phenotype has been conducted only in non-cancer cell models. In these systems, GLI activation has been stimulated by EGF treatment [@pone.0013054-Kasper1], stable GLI1 or HA-RAS expression [@pone.0013054-Yoon1], or expression of constitutively activated GLI2 [@pone.0013054-Eichberger1]. In these studies, CYCLIN D [@pone.0013054-Kasper1], [@pone.0013054-Yoon1], GADD153 [@pone.0013054-Yoon1], CDKN2B, CDKN1A, CDK2, PCNA, TOP2A, CCNB1, XRCC1 [@pone.0013054-Eichberger1], have been identified as genes activated downstream of GLI. In GANT61-treated human colon carcinoma cells, novel DNA damage-inducible transcripts DDIT3 (GADD153), DDIT4 (REDD1), DDIT2 (GADD45G), PPP1R15A (GADD34) and ATF3 were significantly up-regulated concomitant with the arrest of cells at G1/S. TP53INP1, involved in cell cycle regulation, and TP53INP2, linked to cell death responses, were also up-regulated. Additional novel genes involved in S-phase progression and DNA damage response that were significantly down-regulated include KIAA0101 (p15\[PAF\]), Replication Factor C variants 2, 3, 4, 5, CDT1, the E2F transcription factors CDCA4 and TFDP1, MDC1, PCNA, FANCD2, and the genes involved in DNA repair, RAD51C (XRCC3), RAD54B, RAD51 and HELLS.

In summary, we have compared gene expression profiles in two human colon carcinoma cell lines after targeting the function of the transcriptional regulators of HH signaling, GLI1 and GLI2, using the small molecule inhibitor GANT61. Data are consistent with accumulation of cells at the G1/S boundary, as evidenced from flow cytometric analysis, cDNA microarray gene profiling, and qRT- PCR. GANT61-treated cells demonstrated up-regulated expression of the CDK inhibitors p21^Cip1^ and p15^Ink4b^ that function at the G1/S boundary, and down-regulated expression of additional key genes that determine the G1/S transition, initiation of DNA replication, S-phase progression, DNA repair, and subsequent transition through the G2/M phases. Inhibition of the transcriptional regulation of HH signaling in human colon carcinoma cells therefore directly involves genes that regulate cell cycle transition through G1/S, cell cycle progression, and proliferation, and genes involved in stress-induced and DNA damage responses.

Materials and Methods {#s4}
=====================

Human colon carcinoma cell lines {#s4a}
--------------------------------

HT29 was purchased from ATCC (Manassas, VA), while GC3/c1 was established in culture by our group from a human colon adenocarcinoma xenograft model [@pone.0013054-Tillman1]; both cell lines express mutant p53 alleles. Cell lines were maintained in the presence of folate-free RPMI 1640 medium containing 10% dFBS and 80 nM \[6RS\] 5-methyltetrahydrofolate.

Flow cytometric analysis {#s4b}
------------------------

HT29 and GC3/c1 cells were plated at a density of 100,000 cells/well in six-well plates. After overnight attachment, cells were treated with GANT61 (20µM; Enzo Life Sciences, Germany) or vehicle control (DMSO, 0.2%), in duplicate, for 24 hr, followed by washing ×1 with PBS, trypsinization, and centrifugation. Cells were fixed with 70% ethanol at RT, 20--30 min, stored at −20°C overnight, centrifuged for 5 min at 200×g to remove ethanol, and washed ×1 in PBS. The cells were resuspended in PBS, and low molecular weight DNA was extracted using DNA extraction buffer (0.2M Na~2~HPO~4~ and 0.1M citric acid, pH 7.8) for 5 min. The extracted DNA was centrifuged and resuspended in DNA staining solution containing propidium iodide (50 µg) and DNAse-free RNAse (2 mg), and allowed to incubate for 30 min in the dark at RT. Distribution of cells throughout the cell cycle was analyzed using a FACSCalibur flow cytometer, and data were analyzed using CellQuest software.

RNA isolation {#s4c}
-------------

Cells were seeded at 7×10^6^ cells/10 cm plate overnight at ≈60% confluency, and subsequently treated with either vehicle control (0.2% DMSO) or GANT61 (20 µM), in duplicate, for 24 hr. Cells were subsequently harvested and RNA was isolated using the RNeasy® Mini Kit (Qiagen, Valencia, CA) following the manufacturer\'s protocol. Integrity of the RNA was determined by spectrophotometry and electrophoresis.

cDNA microarray analysis {#s4d}
------------------------

RNA (250 ng) was reverse transcribed into cRNA and biotin-UTP labeled using the Illumina® TotalPrep RNA Amplification Kit (Ambion, Applied Biosystems, Foster City, CA) according to the manufacturer\'s protocol. cRNA was quantified using a nanodrop spectrophotometer, and the cRNA quality (size distribution) further analyzed on a 1% agarose gel. Biotinylated cRNAs were hybridized to the Illumina Human-ref8 V3.0 BeadChip (Illumina, San Diego, CA) that represents 18,401 genes, using standard protocols. The arrays were washed and subsequently scanned using an Illumina BeadArray Reader.

Raw signal intensities of gene expression data were processed and analyzed using GenomeStudio (Illumina), with background subtraction and average normalization performed on the average signal intensities, and p-values were calculated. Raw data were exported from GenomeStudio into Excel (available as [Data S1](#pone.0013054.s001){ref-type="supplementary-material"} and [Data S2](#pone.0013054.s002){ref-type="supplementary-material"}), and the fold change in gene expression calculated, by dividing the average gene expression signal intensity of treated samples (GANT61) with that of the vehicle control (DSMO). Differential gene expression (DEG) analysis between control and GANT61-treated samples, was subsequently conducted using the Illumina customer model, which applies multiple testing corrections that determines the false discovery rate (FDR; [@pone.0013054-Reiner1]. Thus, FDR-adjusted differential scores and p-values for each gene/probe set between treated and control samples were generated. Genes with a FDR-adjusted p-value of p\<0.001 and fold change ≥1.5 were considered to be DEGs and were subjected to Venn analysis and Ingenuity Pathway analysis.

These differentially expressed genes were, uploaded and mapped to the library of canonical pathways of the Ingenuity Pathways Analysis (IPA) database for pathway analysis (Ingenuity® Systems, <http://www.ingenuity.com>, Mountain View, CA). The mapped datasets containing either up-regulated or down-regulated genes in HT29 or GC3/c1 cells with corresponding expression values were subjected to core analysis that includes overall canonical pathway enrichment analysis. The significance of enrichment of genes mapped to different canonical pathways was calculated by the Fischer\'s exact test (p-value) to determine the probability that the association between the genes and the canonical pathway could be explained by chance alone. Further, the ratio between the number of identified genes in a particular pathway and total number of genes that make up that pathway provides an estimation of the extent of pathway involvement. The enriched canonical pathways were ranked by −log (p-value) as shown in a histogram of pathway vs. --log (p-value). Datasets containing both up-regulated and down-regulated genes were also analyzed in selected pathways pertaining to cell cycle progression at G1/S and G2/M.

Fold change patterns of most highly DEGs in HT29 and GC3/c1 were compared by Heat map analysis using Matlab (Mathworks) software. DEGs analyzed and displayed in the heat map demonstrated a differential expression p-value of p\<0.001 between control and GANT61 treated cells in both cell lines.

Quantitative Real-Time PCR (qRT-PCR) {#s4e}
------------------------------------

The expression levels of selected genes identified by cDNA microarray expression profiling at 24 hr following GANT61 treatment, were validated by qRT-PCR. Thus, HT29 or GC3/c1 cells were either untreated (vehicle control, 0.2% DMSO), or treated with GANT61 (20 µM) for 0 hr, 16 hr, 24 hr, 38 hr or 48 hr at 37°C, dissolved in DMSO-containing medium. Total RNA (1 µg) was employed to prepare cDNA via reverse transcription using the iScript Select cDNA Synthesis Kit (Biorad) Reverse Transcription System according to manufacturers instructions and analyzed using an Applied Biosystems 7500 PCR Detection System (Applied Biosystems Inc.). All amplifications were primed by pairs of chemically synthesized 18- to 24- mer oligonucleotides designed using freely available primer design software (Primer-BLAST, NCBI) to generate target amplicons of 50--547 bp. All reactions were performed in a final volume of 15 µl. qRT-PCR reaction conditions were as follows: activation at 95°C for 10 min with 40 cycles of denaturation at 95°C for 15 s, primer annealing and extension at 60°C for 1 min and ramping back to 95°C. Melt curve analysis of all samples was routinely performed to ascertain that only the expected products had been generated. A fluorescence reading determined the extent of amplification at the end of each cycle. mRNA expression levels of target genes were normalized to the expression of glyceraldehyde phosphate dehydrogenase (GAPDH) and quantified using the comparative CT method [@pone.0013054-Livak1]. Q-RT-PCR for each gene was determined in duplicate, and each experiment was repeated at least twice.
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